We are live on ! Find out more
DMRA

Damora Therapeutics, Inc. Ordinary Shares

25 hedge funds and large institutions have $30.5M invested in Damora Therapeutics, Inc. Ordinary Shares in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 7

0% more funds holding

Funds holding: 2525 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0.05% less ownership

Funds ownership: 1.65%1.59% (-0.05%)

18% less capital invested

Capital invested by funds: $37.2M → $30.5M (-$6.74M)

Holders
25
Holders Change
Holders Change %
0%
% of All Funds
0.38%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
8
Reduced
7
Closed
4
Calls
$39K
Puts
Net Calls
+$39K
Net Calls Change
+$39K
Name Holding Trade Value Shares
Change
Change in
Stake
VF
26
Virtu Financial
New York
-$88K -983 Closed
TRCT
27
Tower Research Capital (TRC)
New York
-$47K -525 Closed
Osaic Holdings
28
Osaic Holdings
Arizona
-$1K -16 Closed
HI
29
Harbour Investments
Wisconsin
-$1K -12 Closed

DMRA Hedge Fund Activity: Q4 2021 in Review

25 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) for Q4 2021, worth a combined $30.5M — down 18% from $37.2M a quarter earlier.

Fund positioning in DMRA was balanced in Q4 2021: 4 funds opened new positions, 4 closed out, 8 added to existing stakes and 7 trimmed.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $577K. The largest seller was Janus Henderson Group, cutting an estimated $1.65M.

  • 25 institutional investors held Damora Therapeutics, Inc. Ordinary Shares (DMRA) as of Q4 2021, unchanged from Q3 2021.
  • Funds reported $30.5M of Damora Therapeutics, Inc. Ordinary Shares stock for Q4 2021, down 18% quarter-over-quarter.
  • 4 funds opened new Damora Therapeutics, Inc. Ordinary Shares positions in Q4 2021 and 4 closed out, a net change of 0 holders.
  • The largest Damora Therapeutics, Inc. Ordinary Shares buyer in Q4 2021 was Anson Funds Management, an estimated $577K added.
  • The largest Damora Therapeutics, Inc. Ordinary Shares seller in Q4 2021 was Janus Henderson Group, an estimated $1.65M sold.

Based on aggregated 13F filings for Q4 2021.